Low-Dose GLP-1 Plus Glucagon Together Cut Food Intake 13% — When Neither Worked Alone

Thirteen healthy volunteers received four separate 120-minute intravenous infusions in a double-blind, randomized crossover design: low-dose GLP-1 alone, low-dose glucagon alone, both peptides combined, or saline placebo. After 90 minutes, participants ate an ad libitum meal and caloric intake was measured. Resting energy expenditure was assessed by indirect calorimetry at baseline and during infusion. Blood glucose was monitored throughout.

This study is one of the foundational human experiments supporting the development of dual GLP-1/glucagon agonist drugs for obesity. It showed that at carefully calibrated doses, the two peptides complement each other perfectly: GLP-1 handles the appetite reduction and blood sugar protection while glucagon adds energy expenditure boosting. This is the rationale behind drugs like survodutide and other dual agonists now in clinical development.

This 2014 study from Stephen Bloom's lab at Imperial College London was an early and influential proof-of-concept for dual GLP-1/glucagon agonism. It directly informed the development of drugs like survodutide and oxyntomodulin analogs. Interestingly, this study found synergy at low doses — contrasting with the Bagger 2015 study that found no additive effect at higher doses. The difference may relate to dosing: at subanorectic levels, the complementary mechanisms are more apparent.

Small sample of 13 healthy volunteers — not obese or diabetic individuals who would be the target population for dual agonist therapy. The acute single-session design doesn't capture chronic treatment effects. Intravenous infusion doesn't mimic the pharmacokinetics of subcutaneous drug administration. The 53 kcal/day increase in energy expenditure is modest and may not be clinically meaningful. Only male volunteers are mentioned in the MeSH terms.